Evonile Pharma Limited
Key Quantitative Figures
The company plans to issue partly paid-up equity shares via a rights issue for an aggregate amount not exceeding ₹9,000.00 million (Rupees Nine Thousand Million only).
Dates of Action
- October 08, 2026: The Board of Directors initially approved the rights issue.
- October 30, 2026: The company received in-principle approval from BSE Limited for the proposed Rights Issue.
- November 04, 2026: A meeting of the Board of Directors is scheduled to consider and approve the Letter of Offer.
- November 04, 2026: A meeting of the Rights Issue Committee is proposed to determine specific issue details.
Parties Involved
- Regulator/Stock Exchange: BSE Limited
- Issuer: Evonile Pharma Limited (formerly known as Novartis India Limited)
- Company Officer: Chandni Maru, Company Secretary and Compliance Officer
Purpose and Rationale
The purpose of the disclosure is to intimate the stock exchange about the receipt of in-principle approval and the scheduled board meetings to finalize the rights issue details. The rationale for the rights issue is fundraising, as indicated by the aggregate issue size.
Matters for Committee Consideration
The Rights Issue Committee is proposed to meet to consider, decide, and discuss matters including the determination of the issue price, entitlement ratio, record date, and fractional entitlement.
Financial Impact
The financial impact of the rights issue is the potential inflow of up to ₹9,000.00 million upon successful completion. The specific impact on capital structure, including potential dilution, is not quantified in this disclosure and is subject to the committee's determination of the final terms.